Publications

Search our bibliography using the filters on the right-hand side.

Displaying 51 through 79 of 79 publications.

Stull DE, McBride D, Houghton K, Finlay AY, Balp MM. Correlation between UAS7 categorical health states and DLQI score bands to assess burden of disease and response to treatment in chronic idiopathic/spontaneous patients (CIU/CSU). Poster presented at the 23rd World Congress of Dermatology; June 2015. Vancouver, Canada.

Stull DE, McBride D, Houghton K, Balp MM. Are changes in chronic urticaria symptoms and sleep experience correlated?: a post-hoc analysis from phase II trials of omalizumab in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU). Poster presented at the 23rd World Congress of Dermatology; June 2015. Vancouver, Canada.

Stull DE, McBride DW, Houghton KF, Balp MM. Correlation between changes in urticaria symptoms and sleep experience in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU): a post-hoc analysis from 2 randomized, double-blind, placebo-controlled phase 3 trials of omalizumab. Poster presented at the American Academy of Dermatology 73rd Annual Meeting; March 21, 2015. San Francisco, CA. [abstract] J Am Acad Dermatol. 72(5):AB43. doi: 10.1016/j.jaad.2015.02.183

Stull D, McBride D, Houghton K, Finlay A, Gnanasakthy A, Balp MM. Correlations between changes in urticaria activity score, dermatologic-related quality of life, and urticaria-specific quality of life: results from the Ph III trials of omalizumab in CIU/CSU patients. Poster presented at the American Academy of Dermatology 72nd Annual Meeting; March 21, 2015. Denver, CO.

Stull DE, McBride D, Houghton K, Balp MM. A positive correlation between changes in urticaria symptoms (UAS7) and dermatologic-related quality of life (DLQI) and urticaria-specific quality of life (CU-Q2oL): is it informative about the response to treatment in CSU/CIU patients? Poster presented at the Maui Derm for Dermatologists; January 26, 2015. Maui, HI. Previously presented at the Fall Clinical Dermatology Conference.

Stull D, McBride D, Houghton K, Balp M-M. Correlation between changes in urticaria symptoms and sleep experience in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU): results from two randomized, double-blind, placebo-controlled Phase III trials of omalizumab. Poster presented at the Maui Derm for Dermatologists; January 26, 2015. Maui, HI. Previously presented at the Fall Clinical Dermatology Conference.

Stull D, McBride D, Houghton K, Balp M-M. Correlation between changes in urticaria symptoms and sleep experience in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU): results from two randomized, double-blind, placebo-controlled Phase III trials of omalizumab. Poster presented at the Winter Clinical Dermatology Conference; January 16, 2015. Kaanapali, HI. Previously presented at the Fall Clinical Dermatology Conference.

Stull D, McBride D, Houghton K, Balp M-M. A positive correlation between changes in urticaria symptoms (UAS7) and dermatologic-related quality of life (DLQI) and urticaria-specific quality of life (CUQ2oL): is it informative about the response to treatment in csu/ciu patients? Poster presented at the 2015 Winter Clinical Dermatology Conference; January 2015. Kaanapali, HI. Previously presented at the Fall Clinical Dermatology Conference.

Stull D, McBride D, Houghton K, Balp M-M. A positive correlation between changes in urticaria symptoms (UAS7) and dermatologic-related quality of life (DLQI) and urticaria-specific quality of life (CU-Q2oL): is it informative about the response to treatment in CSU/CIU patients? Poster presented at the Fall Clinical Dermatology Conference; October 16, 2014. Las Vegas, NV.

Stull D, McBride D, Houghton K, Balp M-M. Correlation between changes in urticaria symptoms and sleep experience in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU): results from two randomized, double-blind, placebo-controlled, Phase III trials of omalizumab. Poster presented at the Fall Clinical Dermatology Conference; October 16, 2014. Las Vegas, NV.

Stull D, McBride D, Houghton K, Finlay A, Gnanasakthy A, Balp M-M. A positive correlation between changes in urticaria symptoms (UAS7) and dermatologic-related quality of life (DLQI) and urticaria-specific quality of life (CU-Q2oL): is it informative about the response to treatment in CSU/CIU patients? Poster presented at the European Academy of Dermatology and Venereology; October 11, 2014. Amsterdam, the Netherlands. Previously presented at the Fall Clinical Dermatology Conference.

Stull D, McBride D, Houghton K, Finlay A, Gnanasakthy A, Balp M-M. Correlation between changes in urticaria symptoms and sleep experience in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU): results from two randomised, double-blind, placebo-controlled phase III trials of omalizumab. Poster presented at the European Academy of Dermatology and Venereology; October 8, 2014. Amsterdam, the Netherlands. Previously presented at the Fall Clinical Dermatology Conference.

Stull D, McBride D, Houghton K, Finlay A, Gnanasakthy A, Balp MM. Changes in urticaria symptoms, dermatologic-related quality of life, and urticaria-specific quality of life: are they telling us the same thing about response to treatment for chronic spontaneous/idiopathic urticaria (CSU/CIU)? Poster presented at the European Academy of Allergy and Clinical Immunology Congress; June 2014. Copenhagen, Denmark.

Stull D, McBride D, Houghton K, Finlay A, Balp MM. Correlation between changes in weekly disease severity score and quality of life scores in chronic spontaneous/idiopathic urticaria (CSU/CIU): are they equally informative about the response to treatment? Poster presented at the AAAAI Annual Meeting; February 28, 2014. San Diego, CA.

Stull DE, Houghton K. Identifying differential responders and their characteristics in clinical trials: innovative methods for analyzing longitudinal data. Value Health. 2013 Jan 1;16(1):164-76.

Stull DE, Houghton KF, Petrillo J. Innovative data analysis for demonstrating product value: analysis of heterogeneity in treatment response in clinical trials. Ispor Connections. 2013;19(1):5-8.

Stull DE, Houghton KF, Petrillo J. Rethinking analysis of outcome measures for demonstrating value of pharmaceutical products: implications for study design, personalized medicine, and comparative effectiveness research. Presented at the 2012 ISPOR 15th Annual European Congress; November 2012. Berlin, Germany.

Stull DE, Houghton KF, Kulich K. Innovative methods for demonstrating value for pharmaceutical products: rethinking data analysis with implications for study design and personalized medicine. Presented at the International Society for Pharmacoeconomics and Outcomes Research; November 5, 2011. Madrid, Spain.

Stull DE, Houghton KF, Filonenko A. Study heterogeneity in treatment response in women with idiopathic menorrhagia treated with levonorgestrel-releasing intrauterine system (LGN-IUS): application of innovative methods to identify differential response. Presented at the 2011 ISPOR 14th Annual European Congress; November 5, 2011. Madrid, Spain.

Stull DE, Houghton K. Examining variability in depression among pre-retirees: innovative analytic methods applied to observational data. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 9, 2011. [abstract] Value Health. 2011 Nov; 14(7):A301.

Stull DE, Wiklund I, Gale R, Capkun-Niggli G, Houghton K, Jones P. Application of latent growth and growth mixture modeling to identify and characterize differential responders to treatment for COPD. Contemp Clin Trials. 2011 Nov 1;32(6):818-28.

Stull DE, Houghton KF, Gale R, Wiklund I, Capkun-Niggli G, Jones P. Application of innovative methods to identify and characterize differential responders in clinical trials of COPD: the use of mixture models. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 2011. Madrid, Spain. [abstract] Value Health. 2011 Nov; 14(7):A501-2.

Palsgrove A, Houghton KF, Hareendran A, Schaefer M, Setyawan J, Mocarski M, Carson R, Make B. The development of the early morning symptoms of COPD instrument (EMSCI). Poster presented at the 2011 ISPOR 14th Annual European Congress; November 16, 2011. [abstract] Value Health. 2011 Nov; 14(7):A496-7.

Stull DE, van Hanswijck de Jonge P, Houghton K, Kocun C, Sandor DW. Development of a frequent heartburn index. Qual Life Res. 2011 Sep 1;20(7):1023-34.

Stull DE, Houghton KF, Wesnes K. Little or no treatment effect? Application of growth mixture models to explore unknown subgroups of differential responders to treatment. Presented at the 2011 ISPOR 16th Annual International Meeting; May 2011. Baltimore, MD.

Palsgrove A, Schaefer M, Hareendran A, Houghton KF, Mocarski M, Carson R, Make B. The development of a patient-reported outcome instrument to evaluate nighttime symptoms of COPD. Poster presented at the 2011 ISPOR 16th Annual International Meeting; May 2011. Baltimore, MD. [abstract] Value Health. 2011 May; 14(3):A141-2. doi: 10.1016/j.jval.2011.02.788

Schaefer M, Palsgrove A, Hareendran A, Houghton KF, Mocarski M, Carson R, Make B, Setyawan J. Patients' experience of nighttime COPD symptoms: results from qualitative research. Presented at the American Thoracic Society International Conference; 2011.

Stull DE, van Hanswijck de Jonge P, Houghton KF, Kocun C, Sandor DW. Development of the US national frequent heartburn index (HBI) and associated composite score. Presented at the 17th Annual Conference of the International Society for Quality of Life Research; October 27, 2010. London, England.

Stafford M, Houghton KF, Stull DE. Using ATLAS.ti as a tool to extract and synthesize data obtained in literature reviewing. Poster presented at the 2009 Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR); 2009. Paris, France.